| Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies |
30 |
| Amyloid beta oligomers (A beta Os) in Alzheimer's disease |
27 |
| Levodopa-induced dyskinesia: clinical features, incidence, and risk factors |
18 |
| Neuroinflammatory responses in Alzheimer's disease |
18 |
| Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases |
16 |
| Animal models of major depression: drawbacks and challenges |
16 |
| Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease |
15 |
| Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis |
15 |
| Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy |
14 |
| Human tyrosine hydroxylase in Parkinson's disease and in related disorders |
14 |
| Advances in optogenetic and chemogenetic methods to study brain circuits in non-human primates |
13 |
| Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia |
13 |
| The IL-1 beta phenomena in neuroinflammatory diseases |
12 |
| alpha-Synuclein in Parkinson's disease: causal or bystander? |
12 |
| Loss and remodeling of striatal dendritic spines in Parkinson's disease: from homeostasis to maladaptive plasticity? |
12 |
| Olfaction and taste in Parkinson's disease: the association with mild cognitive impairment and the single cognitive domain dysfunction |
12 |
| Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies |
12 |
| The structure of monoamine oxidases: past, present, and future |
11 |
| The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective |
11 |
| Differential contribution of microglia and monocytes in neurodegenerative diseases |
11 |
| Dopamine and addiction: what have we learned from 40 years of research |
10 |
| Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease |
10 |
| Kinetics, mechanism, and inhibition of monoamine oxidase |
10 |
| 90years of monoamine oxidase: some progress and some confusion |
9 |
| Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects |
9 |
| The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies |
9 |
| On the neuronal circuitry mediating l-DOPA-induced dyskinesia |
9 |
| Using wearables to assess bradykinesia and rigidity in patients with Parkinson's disease: a focused, narrative review of the literature |
9 |
| Cortisol levels, motor, cognitive and behavioral symptoms in Parkinson's disease: a systematic review |
9 |
| Association between physical activity and dementia's risk factors in patients with Parkinson's disease |
9 |
| Hippocampal subfield atrophy in patients with Parkinson's disease and psychosis |
8 |
| Diagnostic biomarkers for Parkinson's disease at a glance: where are we? |
8 |
| Basal ganglia, movement disorders and deep brain stimulation: advances made through non-human primate research |
8 |
| The role of depression pharmacogenetic decision support tools in shared decision making |
8 |
| Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review |
8 |
| Dopaminergic modulation of striatal function and Parkinson's disease |
8 |
| Premonitory Urge for Tics Scale (PUTS): replication and extension of psychometric properties in youth with chronic tic disorders (CTDs) |
7 |
| Actigraphy studies and clinical and biobehavioural correlates in schizophrenia: a systematic review |
7 |
| Serotonergic targets for the treatment of L-DOPA-induced dyskinesia |
7 |
| Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease |
7 |
| Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer's disease |
7 |
| Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function |
7 |
| Roles of centromedian parafascicular nuclei of thalamus and cholinergic interneurons in the dorsal striatum in associative learning of environmental events |
7 |
| Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression |
6 |
| Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia |
6 |
| Interleukin 6 and complement serum level study in Parkinson's disease |
6 |
| Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse |
6 |
| Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers |
6 |
| Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease |
6 |
| Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity |
6 |
